TXNIP and chronic myelogenous leukemia, BCR-ABL1 positive: Strikingly, TXNIP knockdown in CML cells increased glucose uptake and lactate production which were suppressed by imatinib (Fig. 5A, B), indicating its inhibitory role in glycolysis.